A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 122, Issue 20, Pages 3432-3439
Publisher
American Society of Hematology
Online
2013-10-04
DOI
10.1182/blood-2013-06-506592
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
- (2013) J. M. Rowe et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
- (2012) Donna S. Neuberg JOURNAL OF CLINICAL ONCOLOGY
- Gemtuzumab Ozogamicin: Time to Resurrect?
- (2012) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia
- (2010) Wassim McHayleh et al. CANCER
- Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
- (2010) Cecile Pautas et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
- (2009) Keith Wheatley et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
- (2009) Thomas R. Chauncey et al. BRITISH JOURNAL OF HAEMATOLOGY
- “I Am Older, Not Elderly,” Said the Patient With Acute Myeloid Leukemia
- (2009) Charles A. Schiffer JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started